Sera Prognostics, Inc. (NASDAQ:SERA) CEO Sells $364,483.63 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 38,899 shares of the business’s stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $9.37, for a total transaction of $364,483.63. Following the completion of the transaction, the chief executive officer now owns 908,104 shares in the company, valued at $8,508,934.48. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Zhenya Lindgardt also recently made the following trade(s):

• On Tuesday, February 6th, Zhenya Lindgardt sold 27,997 shares of Sera Prognostics stock. The stock was sold at an average price of $8.03, for a total transaction of $224,815.91.

Sera Prognostics Stock Down 3.8 %

Shares of SERA opened at $9.10 on Friday. Sera Prognostics, Inc. has a fifty-two week low of $1.52 and a fifty-two week high of $10.44. The firm’s 50 day moving average price is $8.47 and its 200 day moving average price is $5.03. The company has a market cap of $285.17 million, a P/E ratio of -7.84 and a beta of 1.51.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SERA. Frontier Wealth Management LLC acquired a new position in shares of Sera Prognostics in the 1st quarter valued at $30,000. Susquehanna International Group LLP acquired a new position in shares of Sera Prognostics in the 1st quarter valued at $39,000. Goldman Sachs Group Inc. acquired a new position in shares of Sera Prognostics in the 1st quarter valued at $41,000. Charles Schwab Investment Management Inc. acquired a new stake in Sera Prognostics during the 1st quarter worth $46,000. Finally, Bank of New York Mellon Corp acquired a new stake in Sera Prognostics during the 1st quarter worth $50,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.